Cephalosporin-induced hemolytic anemia: a case study
Abstract
Drug-induced immune hemolytic anemia (DIIHA) represents a rare but dangerous medical condition that more often affects children who are administered cephalosporins. A 10-year-old girl developed severe hemolysis after administration of cefuroxime and ceftriaxone for treating an infection linked to parotid lymphangioma. The patient had previously tolerated ceftriaxone and clindamycin but developed dizziness, pallor, and tachycardia, and her hemoglobin (Hb) levels decreased from 12.9 to 2.6 g/dL during her fourth day of treatment, which led to hypovolemic shock and transient renal dysfunction. Our objective is to establish cefuroxime and ceftriaxone as the responsible drugs for DIIHA through immunohematologic testing. The laboratory tests included the direct antiglobulin test (DAT) and the indirect antiglobulin test (IAT) along with drug-dependent antibody testing using the patient's serum (1) to react against group O red blood cells (RBCs) treated with cefuroxime and (2) to react separately against group O RBCs not treated with, but in the presence of, ceftriaxone, with and without complement, at both room temperature and by the IAT. The DAT showed positivity for IgG and C3d. The patient's serum reacted with cefuroxime-treated RBCs by the IAT and reacted with untreated RBCs when ceftriaxone and complement were present. The laboratory results showed that drug-dependent antibodies were present to target RBCs. The patient's condition improved rapidly after stopping cephalosporins…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.